JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - H.C. Wainwright raised its price target on BrainsWay (NASDAQ:BWAY) to $17.00 from $16.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter financial results. According to InvestingPro data, the stock has shown significant momentum, gaining over 7% in the past week and maintaining a "GREAT" overall financial health score.
BrainsWay reported record quarterly net revenue of $12.6 million for Q2 2025, along with net earnings of $0.05 per share. The company shipped 88 Deep TMS systems during the quarter, representing a 35% increase compared to the same period last year, bringing its total installed base to 1,522 systems.
The medical device company maintained a gross margin of 75% in the second quarter, unchanged from the prior-year period. Its adjusted EBITDA increased 16% to $1.5 million, while net profit surged 233% to $2 million compared to $0.6 million in the year-ago quarter.
BrainsWay ended the quarter with $78.3 million in cash, cash equivalents, restricted cash, and short-term deposits as of June 30, 2025. The company reported $62 million in remaining performance obligations from customers under signed multi-year contracts.
H.C. Wainwright noted that approximately 70% of recent customer engagements are structured as multi-year lease agreements, which it expects to be reflected in top-line revenue numbers over the next few years.
In other recent news, BrainsWay Ltd. reported first-quarter revenues of $11.5 million, closely matching H.C. Wainwright’s projection of $11.3 million. The firm’s analyst has adjusted the full-year 2025 revenue forecast to $51.6 million, up from the previous $50.8 million, and slightly increased the 2026 revenue estimate to $60.8 million. BrainsWay also announced preliminary results from a multicenter trial indicating that its accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol for major depressive disorder is as effective as the standard treatment but requires fewer clinic visits. The trial involved 104 adult patients diagnosed with major depressive disorder across eight sites. In a strategic move, BrainsWay has invested $5 million in Stella MSO, LLC, gaining a minority stake and supporting the expansion of mental health clinics in the U.S. and Israel. This investment is part of BrainsWay’s plan to increase access to innovative mental health treatments like Deep TMS Therapy. H.C. Wainwright has maintained its Buy rating and $16.00 price target on BrainsWay stock, underscoring the company’s strategic initiatives and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.